TNBC
Oncology · 2020–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sacituzumab govitecan Amendment to Section 100 Authority Required listing for treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer… | Mar 2025 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab High-risk early-stage triple-negative breast cancer (Stage II-III) in patients who have not received prior systemic therapy, treated with pembrolizumab in… | Jul 2023 | Recommended with restriction | 53 individuals |
| pembrolizumab Early-stage triple negative breast cancer in patients who have not received prior systemic therapy, administered as neoadjuvant therapy in combination with… | Mar 2023 | Not recommended | 12 individuals Breast Cancer Network Australia · Medical Oncology Group |
| pembrolizumab Treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (mTNBC) whose tumours express PD-L1 (CPS ≥10) who have… | Mar 2023 | Recommended with restriction | 35 individuals Breast Cancer Network Australia · Medical Oncology Group |
| sacituzumab govitecan Treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies,… | Mar 2022 | Not recommended | 4 individuals Breast Cancer Network Australia · Rare Cancers Australia · Medical Oncology Group |
| sacituzumab govitecan Treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies,… | Nov 2021 | Not recommended | 4 individuals Breast Cancer Network Australia · Rare Cancers Australia · Medical Oncology Group |
| atezolizumab First-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1 (≥1% on… | Mar 2020 | Not recommended | input received Breast Cancer Network Australia · Medical Oncology Group |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia
What the PBS pays
$927M in government benefit over 2024–25, across 114,042 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| atezolizumab | $156.8M |
| sacituzumab govitecan | $30.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 4 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| pembrolizumabPembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | recommended | 2022-12 |
| sacituzumab govitecanSacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | recommended restricted | 2022-08 |
| pembrolizumab plus chemotherapyPembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | recommended restricted | 2022-06 |
| atezolizumabAtezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | recommended restricted | 2020-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.